Boehringer Ingelheim Espana S.A.

Interstitial lung disease and fibrotic lung disorders

Research activity includes idiopathic pulmonary fibrosis, progressive pulmonary fibrosis, progressive fibrosing interstitial lung diseases, and systemic sclerosis-associated interstitial lung disease, with additional interest in rheumatic disease-related lung fibrosis and lung function decline.

  • Pulmonary fibrosis
  • Interstitial lung disease
  • Systemic sclerosis
  • Respiratory symptom burden

Additional work extends to cough in fibrotic lung disease and related respiratory impairment.

Dermatology and immune-mediated skin disease

The sponsor funds studies in generalized pustular psoriasis, hidradenitis suppurativa, pyoderma gangrenosum, and Netherton syndrome, reflecting a strong focus on severe inflammatory and rare dermatologic conditions.

  • Generalized pustular psoriasis
  • Hidradenitis suppurativa
  • Pyoderma gangrenosum
  • Netherton syndrome

Interest also includes recurrent flares and longer-term management of chronic skin inflammation.

Clinical research spans non-small cell lung cancer, small cell lung carcinoma, HER2-driven solid tumours, pancreatic cancer, biliary tract cancer, urothelial bladder cancer, glioblastoma, glioma, and dedifferentiated liposarcoma.

  • HER2-mutated cancers
  • Advanced solid tumours
  • Pancreatic and biliary cancers
  • Neuro-oncology

Further activity covers extrapulmonary neuroendocrine carcinoma and other advanced malignancies.

Kidney disease, cardiometabolic disease, and heart failure

Research includes chronic kidney disease, proteinuric kidney disease, focal segmental glomerulosclerosis, and other glomerular disorders, alongside studies in type 2 diabetes, obesity, hypertension, and cardiovascular disease.

  • Chronic kidney disease
  • Glomerular disease
  • Type 2 diabetes
  • Cardiovascular risk

Additional interest extends to myocardial infarction, heart failure, and obesity-related metabolic disease.

Liver disease, cystic fibrosis, and rare inflammatory disorders

The portfolio also covers portal hypertension in cirrhosis, including clinically significant portal hypertension, as well as cystic fibrosis and cystic fibrosis-related bronchiectasis. Rare immune and inflammatory conditions such as systemic lupus erythematosus and type 1 interferonopathies are also represented.

  • Portal hypertension
  • Cirrhosis
  • Cystic fibrosis
  • Autoimmune disease

Work in bronchiectasis and related chronic airway disease further broadens the respiratory research focus.

Want to learn more about this study or check if you can participate? Contact us.

Matched clinical trials

  • Study on BI 907828 for Patients with Advanced Biliary Tract, Pancreatic, Lung, or Bladder Cancer

    Not recruiting

    2 1 1
    Austria Belgium France Germany Spain
  • Study on the Safety and Tolerance of BI 1291583 in Adults with Cystic Fibrosis Bronchiectasis

    Not recruiting

    2 1 1
    Investigated diseases:
    Belgium France Germany Italy The Netherlands Spain
  • Study on the Effects of BI 685509 for Patients with Liver Cirrhosis and Portal Hypertension After First Decompensation Event

    Not recruiting

    2 1
    Investigated diseases:
    Investigated drugs:
    Austria France Germany Romania Spain
  • Study on BI 685509 for Adults with Systemic Sclerosis to Assess Effects on Lung Function and Symptoms

    Not recruiting

    2 1
    Investigated drugs:
    Austria Belgium Czechia Denmark Finland France +11
  • Study to Evaluate the Effectiveness of Spesolimab in Treating Patients with Netherton Syndrome

    Not recruiting

    4 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Bulgaria Czechia Finland France +5
  • Study to Evaluate the Effectiveness of Spesolimab for Patients with Moderate to Severe Hidradenitis Suppurativa

    Not recruiting

    4 1
    Investigated drugs:
    Austria Belgium Bulgaria Czechia Denmark Finland +11